Prostate Cell News Volume 3.01 | Jan 13 2012

LABORATORY RESEARCH

New Gene-Immunotherapy Combining TRAIL-Lymphocytes and EpCAMxCD3 Bispecific Antibody for Tumor Targeting
Here, lymphocytes were transduced with TRAIL lentivirus and the anti-tumor effect in presence and absence of EpCAMxCD3 was evaluated in vitro and in xenograft studies using EpCAM-positive pancreatic and prostate cancer cells. [Clin Cancer Res] Abstract

Regulation of Monocyte Chemoattractant Protein-1 through Angiotensin II Type 1 Receptor in Prostate Cancer
In this study, researchers investigated the clinical outcome of monocyte chemoattractant protein-1 (MCP-1) expression in patients with prostate cancer (CaP) and the regulation of MCP-1 through angiotensin II type 1 receptor in CaP. [Am J Pathol] Abstract

Differential Targeting of Androgen and Glucocorticoid Receptors Induces Endoplasmic Reticulum Stress and Apoptosis in Prostate Cancer Cells: A Novel Therapeutic Modality
Researchers’ data validate the concept of dual androgen/glucocorticoid targeting in prostate cancer (PC) and suggest that Bortezomib combination with dual-target steroid receptor modulator compound A has high potential for PC therapy. [Cell Cycle] Abstract

Systemic Blockade of the Hyaluronan Receptor for Endocytosis (HARE) Prevents Lymph Node Metastasis of Prostate Cancer
In this study, researchers tested the hypothesis that HARE can act as an endothelial receptor for metastatic tumor cells with pericellular hyaluronan. [Int J Cancer] Abstract

Hedgehog Signaling in Myofibroblasts Directly Promotes Prostate Tumor Cell Growth
Researchers developed an in vitro co-culture model using microchannel technology to examine the effect of paracrine Hedgehog signaling on proliferation of prostate cancer cells. [Integr Biol] Abstract

MicroRNA-34a Modulates c-Myc Transcriptional Complexes to Suppress Malignancy in Human Prostate Cancer Cells
Researchers studied the functional effects of microRNA-34a (miR-34a) on c-Myc transcriptional complexes in PC-3 prostate cancer cells. [PLoS One] Abstract

Altered CXCR3 Isoform Expression Regulates Prostate Cancer Cell Migration and Invasion
Here, researchers examined the expression and function of two CXCR3 variants in human prostate cancer biopsies and cell lines. [Mol Cancer] Abstract

Increased TGF-ß1-Mediated Suppression of Growth and Motility in Castrate-Resistant Prostate Cancer Cells Is Consistent with Smad2/3 Signaling
This study analyzed prostate cancer responses to TGF-ß signaling in an isogenic model of androgen-sensitive and castration-resistant prostate cancer cells. [Prostate] Abstract

Activation of Nod1 and Nod2 Induces Innate Immune Responses of Prostate Epithelial Cells
In this study, researchers determined whether Nod1 and Nod2 are involved in the innate immune responses of prostate epithelial cells. [Prostate] Abstract

CLINICAL RESEARCH

Germline Mutations in HOXB13 and Prostate-Cancer Risk
Researchers found the novel HOXB13 G84E variant is associated with a significantly increased risk of hereditary prostate cancer. [N Engl J Med] Abstract | Press Release

Bone Scan Index: A Quantitative Treatment Response Biomarker for Castration-Resistant Metastatic Prostate Cancer
This study tested whether treatment-related changes in bone scan index (BSI) are prognostic for survival and compared BSI to prostate-specific antigen as an outcome measure. [J Clin Oncol] Abstract

Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-up
The prostate component of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial was undertaken to determine whether there is a reduction in prostate cancer mortality from screening using serum prostate-specific antigen testing and digital rectal examination. Here, researchers report extended follow-up to 13 years after the trial. [J Natl Cancer Inst] Abstract | Press Release

The Value of Urinary Prostate Cancer Gene 3 (PCA3) Scores in Predicting Pathological Features at Radical Prostatectomy
The objective of this study was to assess correlations between PCA3 levels and pathological features of radical prostatectomy specimens, which define cancer aggressiveness. [BJU Int] Abstract

OncoMed Pharmaceuticals Promotes Dr. Jakob Dupont to Chief Medical Officer
OncoMed Pharmaceuticals, Inc. announced the promotion of Jakob Dupont, M.D., formerly Vice President, Clinical Research, to Senior Vice President and Chief Medical Officer. [OncoMed Pharmaceuticals, Inc.] Press Release

AMGA Welcomes Four New Members to Board of Directors
The American Medical Group Association (AMGA) announced the addition of four new members to its Board of Directors. [American Medical Group Association] Press Release

Cabazitaxel with Radiation and Hormone Therapy May Improve Prostate Cancer Survival
Jefferson’s Kimmel Cancer Center has started a Phase I clinical trial investigating the latest prostate cancer chemotherapy drug to extend survival, Cabazitaxel, in combination with radiation and hormone therapy. [EurekAlert!] Press Release

Research and Development Technologist, hPSC Media (STEMCELL Technologies) 

Scientist – Pluripotent Stem Cells (STEMCELL Technologies)

Scientific Marketing Communications Specialist (STEMCELL Technologies Inc.)

Research Technologist, Manufacturing Sciences (STEMCELL Technologies)

Business Analyst – Product Management (STEMSOFT Software)

Research Associate – Development (Precision Therapeutics, Inc.)

Postdoctoral Research Fellow – Epidemiology / Prostate Studies (Fred Hutchinson Cancer Research Center)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe, Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.